Dishman Carbogen Amcis
- Market cap
- ₹ 2,135 Cr.
- P/E
- 128.7x
- P/B
- 0.33x
- 52-week range
- 128.5 – 303
- ROE
- 2%
- ROCE
- 3%
- Dividend yield
- 0%
- Debt / equity
- 0.46
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Dishman Carbogen Amcis against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)128.7 against a typical 34.3: pricier than most peers (1st = cheapest).200th of 220
- Sales growth−4.2% against a typical +15.6% from a year earlier.155th of 197
- Profit growth−352.2% against a typical +18.9% from a year earlier.157th of 160
- Share price, 3 months−20.7% against a typical −0.5%.181st of 200
- Size₹ 2,134.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).68th of 199
Latest announcements
Exchange filings and their impact on the company.
- Dishman allotted Rs 38 cr of secured NCDs due April 2028, marginally raising debt.
Dishman Carbogen Amcis allotted 3,800 senior, secured, rated, listed NCDs of Rs 1 lakh each, raising Rs 38 crore via private placement on 15 October 2026. The debentures mature on 15 April 2028. The amount is small versus existing borrowings of over Rs 3,000 crore, so it only marginally increases debt and interest cost.
- Board approved a small Rs 38 cr 10% secured NCD issue and swapping land security for cash on existing Rs 15 cr NCDs.
On 7 Oct 2026 Dishman Carbogen Amcis board approved issuing up to Rs 38 crore of 18-month, 10% senior secured NCDs by private placement, secured 1.1x by promoter Dishman Infrastructure land, its corporate guarantee and a 3-month interest reserve. It also approved replacing Dishman Infrastructure's land mortgage for the Rs 15 crore NCDs allotted 28 Sep 2026 with 100% cash margin as fixed-deposit lien. The amounts are small against Rs 3,076 crore borrowings and add about Rs 3.8 crore in annual interest while locking up Rs 15 crore cash.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | Withdrawn | Negative | 4 Jun 2026 |
Every agency has withdrawn its rating.
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 4 Jun 2026 | Withdrawn | was IND A | — | India Ratings | ₹ 1,060.8 Cr. | |
| 18 Feb 2026 | Withdrawn | was IND A | — | India Ratings | ₹ 1,060.9 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 7 Oct 2026 | Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| 14 Aug 2026 | Financial Results | To consider and approve the un-audited financial results for the period ended June 30, 2026 |
| 12 Aug 2026 | Fund Raising | To consider Fund Raising |
| 19 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 18 Mar 2026 | Fund Raising | To consider Fund Raising |
| 3 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 |
| Expenses | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 618 |
| Operating Profit | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 60 |
| OPM % | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% | 16% | 19% | 9% |
| Other Income | 5 | 6 | 4 | −4 | 4 | 8 | −4 | 22 | 8 | 7 | 15 | 16 |
| Interest | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 |
| Depreciation | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 |
| Profit before tax | −36 | −66 | −49 | −78 | 42 | 27 | 28 | 39 | 31 | −10 | 46 | −51 |
| Tax % | 13% | −10% | 42% | 0% | 21% | 83% | −56% | 39% | −114% | 24% | 53% | 13% |
| Net Profit | −41 | −60 | −70 | −78 | 33 | 5 | 43 | 23 | 65 | −13 | 22 | −58 |
| EPS in Rs | −2.61 | −3.8 | −4.46 | −4.95 | 2.11 | 0.3 | 2.75 | 1.49 | 4.16 | −0.83 | 1.39 | −3.69 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- 0%
- 10 Years
- —
- 5 Years
- 21%
- 3 Years
- 140%
- TTM
- −85%
- 10 Years
- —
- 5 Years
- −1%
- 3 Years
- 4%
- TTM
- —
- 10 Years
- 1%
- 5 Years
- 0%
- 3 Years
- 0%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Dishman Carbogen Amcis | ₹ 149.00 | ₹ 2,135 Cr. | 128.7x | 0.3x | 2% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Harshil R. Dalal
- Global Chief Financial Officer
- Shrima Gaurangbhai Dave
- Compliance Officer, Company Secretary
- Arpit Janmejay Vyas
- Global Managing Director, Executive Director
- Deohooti Janmejay Vyas
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.